New syndrome
#############################
Video Source: www.youtube.com/watch?v=-UJqhG1I7tY
Post-Vaccination Syndrome: • A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization • https://www.medrxiv.org/content/10.11... • Yale Listen to Immune, Symptom and Treatment Experiences Now (LISTEN) Study (online) • https://medicine.yale.edu/ycci/listen... • LISTEN study, approved by Yale University Institutional Review Board • Introduction • A chronic post-vaccination syndrome (PVS) after covid-19 vaccination has been reported but has yet to be well characterized. • A chronic syndrome with symptoms that begin soon after vaccination • Methods • People who joined, May 2022 to July 2023 • N = 241 individuals, (211 from the US) • aged 18 and older, • who self-reported PVS after covid-19 vaccination, • Deep immune profiling is used for some individuals • Results • Median age of participants, 46 years • Among participants with PVS • 127 (55%) had received BNT162b2 [Pfizer-BioNTech] • 86 (37%) received the mRNA-1273 [Moderna] • Time from index vaccination to symptom onset • Median time, 3 days (IQR: 1 day to 8 days). • Time from vaccination to symptom survey completion • 595 days (IQR: 417 to 661 days) • Median Euro-QoL visual analogue scale score was 50 (IQR: 39 to 70). • The five most common symptoms • Exercise intolerance (71%) • Excessive fatigue (69%) • Numbness (63%) • Brain fog (63%) • Neuropathy (63%) • In the week before survey completion • (Experienced at least once in the week) • Feeling unease (93%) • Fearfulness (82%) • Overwhelmed by worries (81%) • Feelings of helplessness (80%) • Anxiety (76%) • Depression (76%) • Hopelessness (72%) • Worthlessness (49%) • Concerns related to living situations and food security were also prominent. • Symptom Severity • • When asked to quantify symptom severity on their worst days, • (0 representing a trivial illness and 100 unbearable condition) • Participants reported a median severity of 80 • Interventions to treat their condition • Participants reported a median of 20 (IQR: 13 to 30). • Oral steroids, 116 (48% participants) • Gabapentin, 61 (25%) • Low-dose naltrexone, 48 (20%) • I, 44 (18%) • Propranolol, 27 (11%) • Bronchodilators, 26 (11%) • More than 500 additional treatments were reported by participants • Limiting exercise or exertion • Quitting alcohol or caffeine • Hydration and increasing salt intake • Intermittent fasting • Conclusions • In this study, individuals who reported PVS after covid-19 vaccination had low health status, • high symptom burden, • and high psychosocial stress, • despite trying many treatments. • There is a need for continued investigation to understand and treat this condition. • Looks like you can join, Kindred study • Kindred is a community of patients, working with researchers to power more useful, impactful progress. • https://www.kindred.hugo.health/resea... • https://kindredapp.hugo.health/auth/l...
#############################